Click here to sign up for release emails!
ALIS 6.7 arrives Monday, January 24th, 2022 @12 AM CST.
This release will result in downtime lasting between 30 and 60 minutes, taking place overnight on Monday 1/24 at approximately 12am CST.
Please plan for this downtime and inform your staff. If you have any questions on how to handle this downtime, please contact the Support Team at support@medtelligent.com or your account representative.
Reminder! We recommend using Google Chrome for ALIS. This is especially important for the newer features. Other browsers will not work as well.
Enhanced Alerts Preferences
We have created a better way to assign alerts to your staff and to set them up for yourself.
For each specific category, you can decide the delivery method you want to receive them!
These settings are available for you in your My Account page and on your staff profiles.
Acetaminophen Tracking
The eMAR now provides a way for you to track quantities of Acetaminophen on any order that contains it.
The person passing routine meds and PRNs in ALIS will see a notification if the resident is approaching 3,000 mg of Acetaminophen within a 24 hour period.
If the resident has already received their maximum dose in the 24 hour period, staff will be prompted to Skip Administration and record an exception.
Add beautiful text on Prospect Stories, Notes, and Tasks
We have added a text editor so that you can highlight the most important details and format the information to be easier to read.
Change Occupant Type
We are adding a button to easily change the occupant type for a resident's room assignment.
E-Sign Evaluations and Service Plans
Contact us to set up HelloSign! You can email Evaluation and Service Plans straight from ALIS to your resident's family to collect signatures.
Coming Soon: Integrations to A Place for Mom and Welcome Home
Click here to access the full calendar of ALIS Webinars!
The next scheduled release is March 7th, 2022
Our team is always happy to help! Send your comments or questions to support@medtelligent.com.
Comments
0 comments
Please sign in to leave a comment.